Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huaxintonglin is a Traditional Chinese Medicine (TCM) formulation, typically produced in capsule form, developed by Hubei Huaxin Pharmaceutical. It is primarily indicated for the treatment of urinary tract disorders, including acute and chronic prostatitis, urinary tract infections (UTIs), and urolithiasis (urinary stones). The drug operates based on the TCM principle of clearing 'heat and dampness' from the lower burner, specifically targeting the bladder and prostate. It contains a complex blend of botanical extracts, including *Polygonum aviculare*, *Dianthus superbus*, and *Plantago asiatica*, which collectively exert diuretic, anti-inflammatory, and antibacterial effects. By increasing urine volume and facilitating the flushing of the urinary tract, Huaxintonglin helps alleviate symptoms such as painful urination (dysuria), urgency, and frequency, while also aiding in the passage of small urinary stones.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huaxintonglin.